Studies have shown that SGLT-2 inhibitors are able to attenuate liver fibrosis, improve liver biochemical parameters, reduce fatty liver content (a surrogate of hepatic steatosis), and decrease liver histopathology by attenuating hepatic lipid accumulation and inducing fatty acid oxidation enzyme and autophagy [46, 47]. Here, SLC5A2 is linked to fatty liver disease.